Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.31
-0.0700-5.07%
Post-market: 1.320.0100+0.76%19:58 EDT
Volume:2.49M
Turnover:3.43M
Market Cap:79.48M
PE:-1.87
High:1.48
Open:1.41
Low:1.29
Close:1.38
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.62M
Volume Ratio:4.11
T/O Rate:4.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7000
EPS(LYR):-0.7000
ROE:-745.24%
ROA:-152.76%
PB:33.45
PE(LYR):-1.87

Loading ...

MAIA Showcases THIO-101 NSCLC Data at ELCC 2026

TIPRANKS
·
Mar 27

MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate

Benzinga
·
Mar 24

Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million

Reuters
·
Mar 23

MAIA Biotechnology Completes $30 Million Public Stock Offering

TIPRANKS
·
Mar 05

BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing

Reuters
·
Mar 05

Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing

THOMSON REUTERS
·
Mar 05

Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 05

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

GlobeNewswire
·
Mar 05

BUZZ-MAIA Biotechnology plunges after $30 million share sale

Reuters
·
Mar 03

MAIA Biotechnology 20M share Spot Secondary priced at $1.50

TIPRANKS
·
Mar 03

MAIA Biotechnology announces common stock offering, no amount given

TIPRANKS
·
Mar 03

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Mar 03

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)

TIPRANKS
·
Mar 02

MAIA Biotechnology published a 2026 Letter to Shareholders

TIPRANKS
·
Feb 24

Maia Biotechnology Publishes February 2026 Shareholder Letter

Reuters
·
Feb 24

Maia Biotechnology Announces Availability of 2026 Shareholder Letter

Reuters
·
Feb 24

MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

GlobeNewswire
·
Feb 24

MAIA Biotechnology outlines 2026 goals for ateganosine program

TIPRANKS
·
Jan 21

MAIA Biotechnology highlights milestones, catalysts for FY26

TIPRANKS
·
Jan 20

Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine

Reuters
·
Jan 20